Allergy Therapeutics has today released secondary endpoint results from a study which evaluated the Group’s novel virus-like particle based peanut allergy vaccine candidate. In summarising, Manuel Llobet announced that the study  “…suggest that the vaccine candidate does not only have hypoallergic potential but also has the ability to induce a protective immune-response upon administration.”

Head of Comms Alan Bullimore outlines the key points from the VLP Study in the video below